Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 retatrutide cardiovascular and kidney outcomes trial in adults with overweight or obesity and ASCVD and/or CKD
MOH_2024-03-07_013284Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, chronic kidney disease (CKD), Overweight and 1 more comparing retatrutide with placebo (2 arms). Primary endpoints: Major adverse cardiovascular events and Kidney function decline and kidney-related outcomes. Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)Overweightobesity
Beyond the preview
Go deeper on MOH_2024-03-07_013284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-07_013284.